Q-omics provides the consensus-scored MKRN6P profile across patient tissues and cancer cell-line models. MKRN6P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MKRN6P is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, MKRN6P RNA expression shows 9,834 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, HNSC, and TGCT as cancer lineages where MKRN6P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MKRN6P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MKRN6P survival associations across molecular data types. MKRN6P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MKRN6P RNA expression–survival associations across cancer types. High MKRN6P expression shows unfavorable associations in LIHC, KIRC, ACC, UVM and COAD, but favorable associations in LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MKRN6P RNA expression.
This table summarizes MKRN6P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MKRN6P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MKRN6P shows lower tumor expression in BRCA and COAD and higher tumor expression in HNSC and KIRP. The HNSC box plot shows higher MKRN6P RNA expression in tumor versus normal tissue (log2 FC = +0.625, t-test p < 0.001).
This table shows molecular features associated with MKRN6P in patient tissues and cancer cell lines. In patient samples, MKRN6P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
